Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
CapsoVisionCV +0.16%12 Days Sales Outstanding is 52.48 as of Jun. 2026, which is 13% below its 10-year median of 60.58. GuruFocus rates CV with a GF Score™ of 12/100. The stock has 1 warning sign investors should review. Among 809 Medical Devices & Instruments companies, CapsoVision ranks better than 63.29% on this metric.
CapsoVision's average Accounts Receivable for the
three
months ended in Jun. 2026 was $2.10 Mil. CapsoVision's Revenue for the
three
months ended in Jun. 2026 was $3.64 Mil.
Hence, CapsoVision's Days Sales Outstanding for the
three
months ended in Jun. 2026 was 52.48.
The historical rank and industry rank for CapsoVision's Days Sales Outstanding or its related term are showing as below:
CV'
s Days Sales Outstanding Range Over the Past 10 Years
Min: 54.72 Med: 60.58 Max: 69.83
Current: 54.72
During the past 3 years, CapsoVision's highest Days Sales Outstanding was 69.83. The lowest was 54.72. And the median was 60.58.
CV's Days Sales Outstanding is ranked better than 63.29% of 809
companies
in the Medical Devices & Instruments industry
Industry Median: 64.94
vs CV: 54.72
CapsoVision's Days Sales Outstanding
increased
from Jun. 2025 (48.02) to Jun. 2026 (52.48).
CapsoVision (NAS:CV) Days Sales Outstanding Explanation
For retailers, when we compare Days Sales Outstanding, it is important to compare the same period in the previous years.
CapsoVision Days Sales Outstanding Related Terms
CapsoVision Days Sales Outstanding Historical Data
* Premium members only.
The historical data trend for CapsoVision's Days Sales Outstanding can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
CV vs TLSI, RXST, TMCI: Days Sales Outstanding Comparison
For the Medical Devices subindustry, CapsoVision's Days Sales Outstanding, along with its competitors' market caps and Days Sales Outstanding data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
CapsoVision Days Sales Outstanding vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, CapsoVision's Days Sales Outstanding distribution charts can be found below:
* The bar in red indicates where CapsoVision's Days Sales Outstanding falls into.
Days Sales Outstanding measures the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
CapsoVision (CV) has a Days Sales Outstanding of 52.48 as of Jun. 2026. Days sales outstanding represents the average amount of days a company takes to collect receivables. View historical data on CapsoVision and its competitors. This is 13% below median its historical median of 60.58. Over the past decade, CapsoVision's Days Sales Outstanding has ranged from 54.72 to 69.83. According to the industry distribution chart, CapsoVision ranks #297 out of 809 companies in the Medical Devices & Instruments industry, placing it in the top 36.7%.
Is CapsoVision's Days Sales Outstanding too high?
CapsoVision's current Days Sales Outstanding of 52.48 is 13% below median its 10-year median of 60.58. Over the past 10 years, this metric has ranged from a low of 54.72 to a high of 69.83. The Medical Devices & Instruments industry median Days Sales Outstanding is 64.94. CapsoVision's value of 52.48 is 19.2% below this industry median. Based on the distribution chart, CapsoVision ranks #297 out of 809 companies in the Medical Devices & Instruments industry, which is above the industry midpoint. Overall, CapsoVision has a GF Score™ of 12/100, reflecting its overall financial health beyond just this single metric.
How does CapsoVision's Days Sales Outstanding compare to TLSI and RXST?
According to the Medical Devices & Instruments industry distribution chart, CapsoVision ranks #297 out of 809 companies for Days Sales Outstanding. This puts CapsoVision in the upper half of its industry. The industry median Days Sales Outstanding is 64.94. CapsoVision's value of 52.48 is 19.2% below this benchmark. Historically, CapsoVision's own Days Sales Outstanding has ranged from 54.72 to 69.83 over the past decade. While the company's 10-year median is 60.58 vs. the industry median of 64.94, CapsoVision has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Days Sales Outstanding for a Medical Devices & Instruments company?
The median Days Sales Outstanding among Medical Devices & Instruments companies is 64.94, based on 809 companies in the industry. Companies in the top quartile (top 25%) have a Days Sales Outstanding significantly above this median, while those in the bottom quartile fall well below. However, Days Sales Outstanding should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. CapsoVision's current Days Sales Outstanding of 52.48 is 19.2% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Days Sales Outstanding mean?
A high Days Sales Outstanding can signal that a stock is expensive relative to its fundamentals. Days sales outstanding represents the average amount of days a company takes to collect receivables. View historical data on CapsoVision and its competitors. For the Medical Devices & Instruments industry, the median Days Sales Outstanding is 64.94 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. CapsoVision's current Days Sales Outstanding is 52.48, which is 13% below median its own 10-year median of 60.58. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is CapsoVision stock overvalued right now?
CapsoVision (CV) has a current Days Sales Outstanding of 52.48. The current Days Sales Outstanding is 52.48, which is 13% below median its 10-year median of 60.58 and 19.2% below the Medical Devices & Instruments industry median of 64.94. CapsoVision's overall GF Score™ is 12/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Days Sales Outstanding calculated?
Days Sales Outstanding is calculated from a company's financial statements. For CapsoVision (CV), the current Days Sales Outstanding is 52.48 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
CapsoVision Inc is a commercial-stage medical technology enterprise that innovates, manufactures, and markets endoscopic video imaging devices focused on internal imaging of the gastrointestinal (GI) system. The company's core technology platform is an orally ingestible capsule including multiple cameras facilitating 360-degree imaging, light-emitting diodes for measurement, onboard memory storage, and battery life permitting recording and onboard storage of video images. CapsoVision's products consist of the on-market CapsoCam Plus, directed at the small intestines, and the in-development CapsoColon 3D, directed at the large intestines. Geographically, the company generates the majority of its revenue from the United States.
12GF Score
Get the complete analysis for CV
Days Sales Outstanding is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
CV has been successfully added to your 
